Skip to content
10-Q

Quarterly Report

Traws Pharma, Inc. TRAW

0001104659-25-110845

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 10, 2025 7.99M sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.82M sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.01M sh
Shares Diluted Q3 2025 · Sep 30, 2024 961.53K sh
Shares Diluted Q3 2025 · Sep 30, 2024 1.04M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$15.43M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$25.75M
Current Liabilities Q3 2025 · Sep 30, 2025 $7.89M
Current Liabilities Q3 2025 · Dec 31, 2024 $11.53M
Total Liabilities Q3 2025 · Sep 30, 2025 $7.9M
Total Liabilities Q3 2025 · Dec 31, 2024 $56.59M
Current Assets Q3 2025 · Sep 30, 2025 $9.63M
Current Assets Q3 2025 · Dec 31, 2024 $24.95M
Total Assets Q3 2025 · Sep 30, 2025 $12.44M
Total Assets Q3 2025 · Dec 31, 2024 $24.96M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.34
Eps Diluted Q3 2025 · Sep 30, 2025 $1.53
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$1.49
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$31.86
Eps Basic Q3 2025 · Sep 30, 2025 −$0.34
Eps Basic Q3 2025 · Sep 30, 2025 $1.56
Eps Basic restated Q3 2025 · Sep 30, 2024 −$1.49
Eps Basic restated Q3 2025 · Sep 30, 2024 −$31.86
Sga Expense Q3 2025 · Sep 30, 2025 $1.74M
Sga Expense Q3 2025 · Sep 30, 2025 $6.19M
Sga Expense Q3 2025 · Sep 30, 2024 $3.48M
Sga Expense Q3 2025 · Sep 30, 2024 $8.81M
Net Income Q3 2025 · Sep 30, 2025 −$3.96M
Net Income Q3 2025 · Sep 30, 2025 $16.61M
Net Income Q3 2025 · Sep 30, 2024 −$8.48M
Net Income Q3 2025 · Sep 30, 2024 −$136.6M
Operating Income Q3 2025 · Sep 30, 2025 −$4.06M
Operating Income Q3 2025 · Sep 30, 2025 −$10.51M
Operating Income Q3 2025 · Sep 30, 2024 −$8.54M
Operating Income Q3 2025 · Sep 30, 2024 −$137.1M